Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.73 |
| ▸ | FLT1 | P17948 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426410 | 0.89 | KDR (0.70) | KDRFLT1LMNAPOLBMAPK1 | |
| SCHEMBL429462 | 0.87 | KDR (0.71) | KDRFLT1MAPK1 | |
| SCHEMBL429478 | 0.86 | KDR (0.75) | KDRFLT1 | |
| SCHEMBL14515530 | 0.85 | KDR (0.64) | KDRFLT1LMNAPOLBMAPK1 | |
| SCHEMBL426408 | 0.84 | KDR (1.00) | KDRFLT1 | |
| SCHEMBL429466 | 0.84 | KDR (0.60) | KDRFLT1MAPT | |
| SCHEMBL429755 | 0.81 | HTT (0.52) | KDRPOLBMAPK1 | |
| SCHEMBL3060372 | 0.80 | KDR (0.48) | KDRFLT1MAPK1 | |
| SCHEMBL428979 | 0.78 | KDR (0.56) | KDRFLT1 | |
| SCHEMBL3055165 | 0.78 | KDM5B (0.49) | KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | claimed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | claimed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | KDR 15/4885FLT1 9/4885LMNA 1555/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | KDR 13/4885FLT1 15/4885LMNA 1574/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | KDR 8/4885FLT1 11/4885LMNA 1409/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | KDR 15/4885FLT1 9/4885LMNA 1555/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | KDR 8/4885FLT1 11/4885LMNA 1409/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | KDR 13/4885FLT1 15/4885LMNA 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.